Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 30;25(3):588-594.
doi: 10.17305/bb.2024.11502.

Plasma extracellular vesicle neurofilament light chain as the biomarkers of the progression of Parkinson's disease

Affiliations

Plasma extracellular vesicle neurofilament light chain as the biomarkers of the progression of Parkinson's disease

Chien-Tai Hong et al. Biomol Biomed. .

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by progressive symptoms, underscoring the urgent need for predictive blood biomarkers. Plasma extracellular vesicles (EVs) offer a promising platform for biomarker development, with neurofilament light chain (NfL) emerging as a potential candidate for neurological diseases. This study evaluated plasma EV NfL as a biomarker for disease progression in a PD cohort.A total of 55 patients with PD (PwP) and 58 healthy controls (HCs) were followed, with PwP completing an average of 3.96 visits and HCs 2.25 visits. Plasma EVs were isolated and validated, and EV NfL levels were measured using an immunomagnetic reduction assay. Generalized estimating equations and Spearman correlations assessed relationships between clinical symptom progression and biomarkers. Although no significant differences in plasma EV NfL levels were observed between PwP and HCs over time, changes in plasma EV NfL significantly correlated with motor symptom progression, specifically with adjusted-total and akinetic-rigidity subscores of the Unified PD Rating Scale (UPDRS) Part III. Additionally, changes in UPDRS Part II scores were significantly associated with plasma EV NfL levels. These findings suggest that plasma EV NfL reflects motor symptom progression in PwP, highlighting its potential as a valuable biomarker for monitoring disease progression and guiding clinical trials in PD.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
(A) The progression of motor symptoms (assessed by total score of UPDRS part III) and (B) cognition (assessed by MMSE) in people with Parkinson’s disease. Data was presented as dot plot. MMSE: Mini-Mental State Examination; UPDRS: Unified Parkinson’s Disease Rating Scale.
Figure 2.
Figure 2.
Levels of plasma EV NfL in PwP and HCs. Generalized estimating equations were utilized to compare the change of plasma EV NfL between PwP with HCs. Data are presented as median (interquartile range). EV: Extracellular vesicle; NfL: Neurofilament light chain; HC: Healthy control; PwP: People with Parkinson’s disease.
Figure 3.
Figure 3.
The association between the change of plasma extracellular vesicle neurofilament light chain with the change of adjusted UPDRS part III (A), and the change of adjusted MMSE (B). The UPDRS part III and MMSE were standardized to Z scores with the adjustment of age and gender variations across different visits. EV: Extracellular vesicle; NfL: Neurofilament light chain; MMSE: Mini-Mental State Examination; UPDRS: Unified Parkinson’s Disease Rating Scale; AR: Akinetic rigidity.

Similar articles

References

    1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–303. https://doi.org/10.1016/S0140-6736(21)00218-X. - PubMed
    1. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–60. https://doi.org/10.1001/jama.2019.22360. - PubMed
    1. Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol. 2019;18(6):573–86. https://doi.org/10.1016/S1474-4422(19)30024-9. - PubMed
    1. Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, et al. Parkinson’s disease biomarkers based on α-synuclein. J Neurochem. 2019;150(5):626–36. https://doi.org/10.1111/jnc.14809. - PubMed
    1. Qu Y, Li J, Qin Q, Wang D, Zhao J, An K, et al. A systematic review and meta-analysis of inflammatory biomarkers in Parkinson’s disease. NPJ Parkinson’s Dis. 2023;9(1):18. https://doi.org/10.1038/s41531-023-00449-5. - PMC - PubMed